tDCS & Auditory Hallucinations in Schizophrenia (AVH-SZ)

Herzog Hospital1 site in 1 country3 target enrollmentMarch 2014

ConditionsSchizophrenia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Schizophrenia
Sponsor: Herzog Hospital
Enrollment: 3
Locations: 1
Primary Endpoint: change from baseline in auditory hallucination rating scale
Status: Terminated
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this study is to evaluate tDCS effects on schizophrenia symptoms, particularly on auditory verbal hallucinations. tDCS applied with cathodal (inhibitory) electrode over the left temporal parietal junction and anodal (excitatory) electrode over the left dorsolateral prefrontal cortex.

Registry

clinicaltrials.gov

Start Date

March 2014

End Date

August 2016

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Herzog Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Ages 18-60
•Primary diagnosis of Diagnostic and Statistical Manual, fifth edition, schizophrenia
•Persistent auditory verbal hallucinations
•Right handed
•Under stable doses of antipsychotic medication for ≥4 weeks
•Normal hearing by self-report and physical exam
•Use of effective method of birth control for women of childbearing capacity
•Capable to provide informed consent. For patients judged to be incapable to provide informed consent the legal guardian of the patient must agree to participation in the study and provide signed informed consent

Exclusion Criteria

•Current or past history of substance dependence or abuse (excluding nicotine)
•Other current Axis I disorders
•History of seizure, epilepsy in self or first degree relatives, stoke, brain surgery, head injury, intracranial metal implants, known structural brain lesion, devices that may be affected by tDCS (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
•Frequent and persistent migraines
•History of adverse reaction to neurostimulation
•Participation in study of investigational medication within 6 weeks
•Pregnancy
•Women who are breast-feeding
•Current significant laboratory abnormality